Systemic inflammation originating in the body’s periphery—rather than the brain itself—may be a primary driver of Parkinson’s disease, according to research published in Cell Reports. Scientists suggest that the LRRK2 mutation, common in Parkinson’s patients, triggers a cycle where cellular waste is packaged into extracellular vesicles (EVs) that cross the blood-brain barrier, effectively transporting inflammatory signals to the brain to initiate neurodegeneration.
The Peripheral Origins of Neurodegeneration
For decades, the brain was viewed as an immune-privileged site, isolated from the systemic immune responses occurring in the rest of the body. Recent findings from an international research collective, including work by Öberg et al. (2026), challenge this, suggesting that the “inflammaging” process—chronic, low-grade systemic inflammation—plays a critical role in brain health.
The study identifies the cGAS-STING pathway as a central molecular engine. In healthy cells, this pathway detects foreign DNA from pathogens. However, in aging or mutated cells, the degradation of the endolysosomal system causes a cell’s own damaged DNA to accumulate in the cytosol. The cGAS sensor cannot distinguish this “self” DNA from a virus, triggering a smoldering, chronic interferon type I (IFN-I) response. In patients with the LRRK2 G2019S mutation, this recycling mechanism is defective, accelerating the production of these inflammatory signals.
Did you know?
The researchers observed that in Lrrk2GoF mice, the peripheral IFN-I signature was detectable as early as 3 months of age, while brain inflammation and motor decline did not manifest until 12 months, supporting the theory that the disease process begins outside the central nervous system.
Extracellular Vesicles as “Trojan Horses”
The mechanism by which this inflammation reaches the brain involves extracellular vesicles (EVs). When cells cannot properly degrade their waste due to LRRK2 mutations, they increase the secretion of EVs containing genomic and mitochondrial DNA. These vesicles act as “Trojan horses,” carrying inflammatory triggers across the blood-brain barrier.
Data from the study shows a clear link between these vesicles and disease progression:
- Human Data: Plasma and cerebrospinal fluid (CSF) from Parkinson’s patients contained higher levels of DNA-carrying EVs compared to healthy donors.
- Causality: When these patient-derived EVs were introduced to recipient macrophages, they induced a STING-dependent inflammatory response.
- Intervention: Deleting the STING gene in Lrrk2GoF mice prevented the loss of 51% of dopaminergic neurons, a hallmark of Parkinson’s, and halted motor decline.
Future Trends in Parkinson’s Therapeutic Development
The discovery that STING inhibition can reverse inflammatory responses in both peripheral tissues and the brain opens new avenues for Parkinson’s treatment. Current pharmaceutical research is focusing on the LRRK2 pathway, as inhibitors have already shown success in normalizing IFNB1 transcripts in blood monocytes from Parkinson’s patients.
Frequently Asked Questions
Can systemic inflammation cause Parkinson’s disease?
According to the study in Cell Reports, systemic inflammation driven by the cGAS-STING pathway appears to contribute to Parkinson’s. Mutations like LRRK2 cause peripheral cells to export inflammatory signals via extracellular vesicles that can reach the brain.
What is the role of the LRRK2 mutation?
LRRK2 regulates the cell’s degradation and recycling machinery. The G2019S mutation increases the enzyme’s activity, leading to defective waste clearance, accumulation of self-DNA in the cytosol, and increased secretion of inflammatory extracellular vesicles.
How does inflammation reach the brain?
The research suggests that extracellular vesicles (EVs) act as carriers for DNA that triggers the cGAS-STING pathway. These vesicles enter the bloodstream and eventually cross the blood-brain barrier, where they activate microglia and neurons, leading to neuroinflammation.
Pro Tip:
Stay updated on the latest developments in neuroimmunology by subscribing to our newsletter. We analyze the latest findings in cellular degradation pathways and their impact on age-related diseases.
[Subscribe Here]
Have questions about how systemic health impacts neurological outcomes? Join the conversation in the comments section below.
